Cargando…
Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
INTRODUCTION: Lurasidone is an atypical antipsychotic that was approved in Europe in 2014 for the treatment of schizophrenia in adults aged ≥ 18 years. Clinical experience with lurasidone in Europe is currently limited, and there is therefore a need to provide practical guidance on using lurasidone...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858892/ https://www.ncbi.nlm.nih.gov/pubmed/31098889 http://dx.doi.org/10.1007/s40120-019-0138-z |
_version_ | 1783471044541022208 |
---|---|
author | Javed, Afzal Arthur, Holger Curtis, Logos Hansen, Lars Pappa, Sofia |
author_facet | Javed, Afzal Arthur, Holger Curtis, Logos Hansen, Lars Pappa, Sofia |
author_sort | Javed, Afzal |
collection | PubMed |
description | INTRODUCTION: Lurasidone is an atypical antipsychotic that was approved in Europe in 2014 for the treatment of schizophrenia in adults aged ≥ 18 years. Clinical experience with lurasidone in Europe is currently limited, and there is therefore a need to provide practical guidance on using lurasidone for the treatment of adults with schizophrenia. METHODS: A panel of European psychiatrists with extensive experience of prescribing lurasidone was convened to provide recommendations on using lurasidone to treat adults with schizophrenia. RESULTS: Extensive evidence from clinical trials and the panel’s clinical experience suggest that lurasidone is as effective as other atypical agents, with the possible exception of clozapine. Lurasidone is associated with a lower propensity for metabolic side effects (in particular, weight gain) and hyperprolactinaemia than most other atypical antipsychotics and has a relatively benign neurocognitive side effect profile. Patients switching to lurasidone from another antipsychotic may experience weight reduction and/or improvements in the ability to focus/concentrate. Most side effects with lurasidone (such as somnolence) are transitory, easily managed and/or ameliorated by dose adjustment. Akathisia and extrapyramidal symptoms may occur in a minority of patients, but these can be managed effectively with dose adjustment, adjunctive therapy and/or psychosocial intervention. CONCLUSIONS: Given the crucial importance of addressing the physical as well as mental healthcare needs of patients, lurasidone is a rational therapeutic choice for adults with schizophrenia, both in the acute setting and over the long term. FUNDING: Sunovion Pharmaceuticals Europe Ltd. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40120-019-0138-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6858892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-68588922019-12-16 Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia Javed, Afzal Arthur, Holger Curtis, Logos Hansen, Lars Pappa, Sofia Neurol Ther Commentary INTRODUCTION: Lurasidone is an atypical antipsychotic that was approved in Europe in 2014 for the treatment of schizophrenia in adults aged ≥ 18 years. Clinical experience with lurasidone in Europe is currently limited, and there is therefore a need to provide practical guidance on using lurasidone for the treatment of adults with schizophrenia. METHODS: A panel of European psychiatrists with extensive experience of prescribing lurasidone was convened to provide recommendations on using lurasidone to treat adults with schizophrenia. RESULTS: Extensive evidence from clinical trials and the panel’s clinical experience suggest that lurasidone is as effective as other atypical agents, with the possible exception of clozapine. Lurasidone is associated with a lower propensity for metabolic side effects (in particular, weight gain) and hyperprolactinaemia than most other atypical antipsychotics and has a relatively benign neurocognitive side effect profile. Patients switching to lurasidone from another antipsychotic may experience weight reduction and/or improvements in the ability to focus/concentrate. Most side effects with lurasidone (such as somnolence) are transitory, easily managed and/or ameliorated by dose adjustment. Akathisia and extrapyramidal symptoms may occur in a minority of patients, but these can be managed effectively with dose adjustment, adjunctive therapy and/or psychosocial intervention. CONCLUSIONS: Given the crucial importance of addressing the physical as well as mental healthcare needs of patients, lurasidone is a rational therapeutic choice for adults with schizophrenia, both in the acute setting and over the long term. FUNDING: Sunovion Pharmaceuticals Europe Ltd. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40120-019-0138-z) contains supplementary material, which is available to authorized users. Springer Healthcare 2019-05-16 /pmc/articles/PMC6858892/ /pubmed/31098889 http://dx.doi.org/10.1007/s40120-019-0138-z Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Commentary Javed, Afzal Arthur, Holger Curtis, Logos Hansen, Lars Pappa, Sofia Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia |
title | Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia |
title_full | Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia |
title_fullStr | Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia |
title_full_unstemmed | Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia |
title_short | Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia |
title_sort | practical guidance on the use of lurasidone for the treatment of adults with schizophrenia |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858892/ https://www.ncbi.nlm.nih.gov/pubmed/31098889 http://dx.doi.org/10.1007/s40120-019-0138-z |
work_keys_str_mv | AT javedafzal practicalguidanceontheuseoflurasidoneforthetreatmentofadultswithschizophrenia AT arthurholger practicalguidanceontheuseoflurasidoneforthetreatmentofadultswithschizophrenia AT curtislogos practicalguidanceontheuseoflurasidoneforthetreatmentofadultswithschizophrenia AT hansenlars practicalguidanceontheuseoflurasidoneforthetreatmentofadultswithschizophrenia AT pappasofia practicalguidanceontheuseoflurasidoneforthetreatmentofadultswithschizophrenia |